Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14583809 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL21783270 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL13424410 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL13562761 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL2582793 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL2580825 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL12152898 | 0.82 | BCHE (0.49) | BCHEACHEPDE4DPDPK1MTOR | |
| SCHEMBL15877138 | 0.81 | ALDH1A1 (0.38) | BCHEACHEPDE4DAXLMERTK | |
| SCHEMBL14957991 | 0.81 | NPC1 (0.39) | BCHEACHEPDE4D | |
| SCHEMBL21783307 | 0.80 | BCHE (0.46) | BCHEACHEEPHX2PDE4DPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744338-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2569291-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2016-04-06 | — | — | EP | disclosed |
| US-9120781-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-09-01 | — | — | US | disclosed |
| EP-2744338-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-05-23 | — | — | US | disclosed |
| WO-2013025452-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | BCHE 632/4885ACHE 1227/4885EPHX2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.